CS1 added to standard care for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This trial tests whether adding the study drug CS1 to your usual PAH treatment helps improve symptoms and daily function. It is for people with moderate symptoms who are already on stable PAH therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with pulmonary arterial hypertension (PAH) confirmed by a heart catheterization.
- Your symptoms are mild to moderate (WHO Functional Class II or III).
- You have been on the same PAH medications for at least 90 days before joining.
- You can walk at least 150 meters (about 1.5 football fields) but less than 550 meters in 6 minutes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
This trial studies whether spironolactone can improve pulmonary arterial hypertension, a disease that makes the blood vessels in the lungs work too hard. You may be eligible if your condition is confirmed by specific heart-lung pressure tests and your medication plan has been stable for at least 4 weeks.
This trial tests whether a blood pressure medicine called valsartan can help protect the lungs and heart in people with a specific type of pulmonary hypertension (Group 1 PAH). If you have PAH and are stable enough to walk 50 meters, you may be able to join.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.